Alternative molecular formats and therapeutic applications for bispecific antibodies. Issue 2 (October 2015)

• Record Type: Journal Article
• Authors: Spiess, Christoph; Zhai, Qianting; Carter, Paul J.
• Is Part Of: Molecular immunology. Volume 67:Issue 2(2015:Oct.)Part A
• Page Start: 95
• Page End: 106
• Publication Date: 2015-10
• Subjects: ADCC antibody-dependent cellular cytotoxicity -- ADCP antibody-dependent cellular phagocytosis -- ALL acute lymphoblastic leukemia -- AMD age-related macular degeneration -- AML acute myeloid leukemia -- BsAb bispecific antibody -- BsIgG bispecific IgG -- CDC complement-dependent cytotoxicity -- CEA carcinoembryonic antigen -- CLL chronic lymphocytic leukemia -- DAF dual action Fab -- DART dual-affinity retargeting -- DLBCL diffuse large B-cell lymphoma -- FDA Food and Drug Administration -- ImmTACs immune-mobilizing monoclonal T cell receptors against cancer -- MAPG melanoma-associated proteoglycan -- NHL non-Hodgkin's lymphoma.; Bispecific antibodies -- Antibody engineering -- Antibody therapeutics; Immunochemistry -- Periodicals; Molecular biology -- Periodicals; Immunochemistry -- Periodicals; Allergy and Immunology -- Periodicals; Molecular Biology -- Periodicals; Immunochimie -- Périodiques; Biologie moléculaire -- Périodiques; Immunochemistry; Molecular biology; Periodicals; Electronic journals; 571.96
• DOI: 10.1016/j.molimm.2015.01.003
• Languages: English
• ISSNs: 0161-5890

Abstract

Highlights: Bispecific antibodies (BsAb) bind 2 distinct antigens or epitopes on the same antigen. Antibody domain structure has been exploited to make >60 alternative BsAb formats. 2 BsAb are approved for therapy and >30 BsAb are in clinical development. A common clinical application of BsAb is retargeting T cells to kill tumor cells. Other clinical uses of BsAb include dual blockade of different disease mediators. Abstract: Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they were first described. Two bispecific antibodies, catumaxomab (Removab ®, anti-EpCAM × anti-CD3) and blinatumomab (Blincyto ®, anti-CD19 × anti-CD3) are approved for therapy, and >30 additional bispecific antibodies are currently in clinical development. Many of these investigational bispecific antibody drugs are designed to retarget T cells to kill tumor cells, whereas most others are intended to interact with two different disease mediators such as cell surface receptors, soluble ligands and other proteins. The modular architecture of antibodies has been exploited to create more than 60 different bispecific antibody formats. These formats vary in many ways including their molecular weight, number of antigen-binding sites, spatial relationship between different binding sites, valency for each antigen, ability to support secondary immune functions and pharmacokinetic half-life. These diverse formats provide great opportunity to tailor the design of bispecific antibodies to match the proposed mechanisms of action and the intended clinical application.